In 2019, Liuet al. reported a highly selective HDAC6 inhibitor 149 with PROTAC-like efficacy for the treatment of GBM.548 Compound 149 caused p62 accumulationand proteasomal degradation, leading to proteolysis of aberrantlyoverexpressed HDAC6 isoforms in GBM. Here, SQSTM1 is linked to glioblastoma.